A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock

International Immunopharmacology

Volumn 21, Issue 1, 2014, Pages 208-219

  Sigalov, Alexander B ^a  

^a SignaBlok Inc   (United States)

Author keywords

HDL nanoparticles; Non small cell lung cancer; Sepsis; Targeted delivery; Therapeutic SCHOOL peptides; TREM 1 receptor

Indexed keywords

ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; DEXAMETHASONE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGAND; LIPOPOLYSACCHARIDE; NANOPARTICLE; PACLITAXEL; SYNTHETIC PEPTIDE; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 INHIBITOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1 SIGNALING CHAIN HOMOOLIGOMERIZATION PEPTIDE GF9; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; IMMUNOGLOBULIN RECEPTOR; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; TREM1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RESPONSE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENE DELIVERY SYSTEM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOPOLYSACCHARIDE-INDUCED ENDOTOXEMIA; LUNG CANCER; MACROPHAGE; MOUSE; NONHUMAN; PLASMA HALF LIFE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL GROWTH; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PERITONEUM MACROPHAGE; SHOCK, SEPTIC; TUMOR CELL LINE; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOKINES; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; LIPOPROTEINS, HDL; LUNG NEOPLASMS; MACROPHAGES, PERITONEAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, NUDE; NANOPARTICLES; PEPTIDE FRAGMENTS; RECEPTORS, IMMUNOLOGIC; SHOCK, SEPTIC; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901009820     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2014.05.001     Document Type: Article

References (70)

1. E. Felip, M. Santarpia, and R. Rosell Emerging drugs for non-small-cell lung cancer Expert Opin Emerg Drugs 12 2007 449 460
2. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
3. G. Solinas, G. Germano, A. Mantovani, and P. Allavena Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation J Leukoc Biol 86 2009 1065 1073
4. J.-Y. Shih, A. Yuan, J.J.-W. Chen, and P.-C. Yang Tumor-associated macrophage: its role in cancer invasion and metastasis J Cancer Mol 2 2006 101 106
5. T.J. Welsh, R.H. Green, D. Richardson, D.A. Waller, K.J. O'Byrne, and P. Bradding Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer J Clin Oncol 23 2005 8959 8967
6. K.D. Elgert, D.G. Alleva, and D.W. Mullins Tumor-induced immune dysfunction: the macrophage connection J Leukoc Biol 64 1998 275 290
7. J. Kaminska, M. Kowalska, B. Kotowicz, M. Fuksiewicz, M. Glogowski, and E. Wojcik et al. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor Oncology 70 2006 115 125
8. J. Cohen The immunopathogenesis of sepsis Nature 420 2002 885 891
9. G.S. Martin, D.M. Mannino, S. Eaton, and M. Moss The epidemiology of sepsis in the United States from 1979 through 2000 N Engl J Med 348 2003 1546 1554
10. A. Ayala, and I.H. Chaudry Immune dysfunction in murine polymicrobial sepsis: mediators, macrophages, lymphocytes and apoptosis Shock 6 Suppl. 1 1996 S27 S38
11. H. Oren, N. Duman, H. Abacioglu, H. Ozkan, and G. Irken Association between serum macrophage colony-stimulating factor levels and monocyte and thrombocyte counts in healthy, hypoxic, and septic term neonates Pediatrics 108 2001 329 332
12. C.A. Gogos, E. Drosou, H.P. Bassaris, and A. Skoutelis Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options J Infect Dis 181 2000 176 180
13. A. Bouchon, F. Facchetti, M.A. Weigand, and M. Colonna TREM-1 amplifies inflammation and is a crucial mediator of septic shock Nature 410 2001 1103 1107
14. L. Luo, Q. Zhou, X.J. Chen, S.M. Qin, W.L. Ma, and H.Z. Shi Effects of the TREM-1 pathway modulation during empyema in rats Chin Med J (Engl) 123 2010 1561 1565
15. Y. Murakami, T. Akahoshi, N. Aoki, M. Toyomoto, N. Miyasaka, and H. Kohsaka Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis Arthritis Rheum 60 2009 1615 1623
16. M. Schenk, A. Bouchon, F. Seibold, and C. Mueller TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases J Clin Invest 117 2007 3097 3106
17. K. Dower, D.K. Ellis, K. Saraf, S.A. Jelinsky, and L.L. Lin Innate immune responses to TREM-1 activation: overlap, divergence, and positive and negative cross-talk with bacterial lipopolysaccharide J Immunol 180 2008 3520 3534
18. C.C. Ho, W.Y. Liao, C.Y. Wang, Y.H. Lu, H.Y. Huang, and H.Y. Chen et al. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer Am J Respir Crit Care Med 177 2008 763 770
19. T. van Bremen, D. Dromann, K. Luitjens, C. Dodt, K. Dalhoff, and T. Goldmann et al. Triggering receptor expressed on myeloid cells-1 (Trem-1) on blood neutrophils is associated with cytokine inducibility in human E. coli sepsis Diagn Pathol 8 2013 24
20. S. Gibot Clinical review: role of triggering receptor expressed on myeloid cells-1 during sepsis Crit Care 9 2005 485 489
21. S. Gibot, F. Massin, M. Marcou, V. Taylor, R. Stidwill, and P. Wilson et al. TREM-1 promotes survival during septic shock in mice Eur J Immunol 37 2007 456 466
22. F. Wang, S. Liu, S. Wu, Q. Zhu, G. Ou, and C. Liu et al. Blocking TREM-1 signaling prolongs survival of mice with Pseudomonas aeruginosa induced sepsis Cell Immunol 272 2012 251 258
23. S. Gibot, F. Massin, C. Alauzet, M. Derive, C. Montemont, and S. Collin et al. Effects of the TREM 1 pathway modulation during hemorrhagic shock in rats Shock 32 2009 633 637
24. J. Zhou, F. Chai, G. Lu, G. Hang, C. Chen, and X. Chen et al. TREM-1 inhibition attenuates inflammation and tumor within the colon Int Immunopharmacol 17 2013 155 161
25. A.B. Sigalov Immune cell signaling: a novel mechanistic model reveals new therapeutic targets Trends Pharmacol Sci 27 2006 518 524
26. A. Sigalov, O. Alexandrovich, and E. Strizevskaya Large-scale isolation and purification of human apolipoproteins A-I and A-II J Chromatogr 537 1991 464 468
27. A.B. Sigalov, and L.J. Stern Enzymatic repair of oxidative damage to human apolipoprotein A-I FEBS Lett 433 1998 196 200
28. U.K. Laemmli Cleavage of structural proteins during the assembly of the head of bacteriophage T4 Nature 227 1970 680 685
29. M.N. Oda, P.L. Hargreaves, J.A. Beckstead, K.A. Redmond, R. van Antwerpen, and R.O. Ryan Reconstituted high density lipoprotein enriched with the polyene antibiotic amphotericin B J Lipid Res 47 2006 260 267
30. A.B. Sigalov, and L.J. Stern Oxidation of methionine residues affects the structure and stability of apolipoprotein A-I in reconstituted high density lipoprotein particles Chem Phys Lipids 113 2001 133 146
31. A.B. Sigalov Nature-inspired nanoformulations for contrast-enhanced in vivo MR imaging of macrophages Contrast Media Mol Imaging 2014 [in press]
32. W.J. McConathy, M.P. Nair, S. Paranjape, L. Mooberry, and A.G. Lacko Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel Anticancer Drugs 19 2008 183 188
33. M.A. Markwell, S.M. Haas, L.L. Bieber, and N.E. Tolbert A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples Anal Biochem 87 1978 206 210
34. P.P. Van Veldhoven, and G.P. Mannaerts Inorganic and organic phosphate measurements in the nanomolar range Anal Biochem 161 1987 45 48
35. T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 1983 55 63
36. J.I. Johnson, S. Decker, D. Zaharevitz, L.V. Rubinstein, J.M. Venditti, and S. Schepartz et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials Br J Cancer 84 2001 1424 1431
37. W. Chen, E. Vucic, E. Leupold, W.J. Mulder, D.P. Cormode, and K.C. Briley-Saebo et al. Incorporation of an apoE-derived lipopeptide in high-density lipoprotein MRI contrast agents for enhanced imaging of macrophages in atherosclerosis Contrast Media Mol Imaging 3 2008 233 242
38. S. Gupta, A. Jain, M. Chakraborty, J.K. Sahni, J. Ali, and S. Dang Oral delivery of therapeutic proteins and peptides: a review on recent developments Drug Deliv 20 2013 237 246
39. A. Scanu, and W.L. Hughes Further characterization of the human serum D 1.063-1.21, alpha-lipoprotein J Clin Invest 41 1962 1681 1689
40. R.H. Furman, S.S. Sanbar, P. Alaupovic, R.H. Bradford, and R.P. Howard Studies of the metabolism of radioiodinated human serum alpha lipoprotein in normal and hyperlipidemic subjects J Lab Clin Med 63 1964 193 204
41. S. Gibot, M.N. Kolopp-Sarda, M.C. Bene, P.E. Bollaert, A. Lozniewski, and F. Mory et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis J Exp Med 200 2004 1419 1426
42. S. Gibot, C. Buonsanti, F. Massin, M. Romano, M.N. Kolopp-Sarda, and F. Benigni et al. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock Infect Immun 74 2006 2823 2830
43. A. Bouchon, J. Dietrich, and M. Colonna Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes J Immunol 164 2000 4991 4995
44. J.R. Bleharski, V. Kiessler, C. Buonsanti, P.A. Sieling, S. Stenger, and M. Colonna et al. A role for triggering receptor expressed on myeloid cells-1 in host defense during the early-induced and adaptive phases of the immune response J Immunol 170 2003 3812 3818
45. A.S. Tessarz, and A. Cerwenka The TREM-1/DAP12 pathway Immunol Lett 116 2008 111 116
46. J. Klesney-Tait, I.R. Turnbull, and M. Colonna The TREM receptor family and signal integration Nat Immunol 7 2006 1266 1273
47. D.Y. Wang, R.Y. Qin, Z.R. Liu, M.K. Gupta, and Q. Chang Expression of TREM-1 mRNA in acute pancreatitis World J Gastroenterol 10 2004 2744 2746
48. A.B. Sigalov Multichain immune recognition receptor signaling: different players, same game? Trends Immunol 25 2004 583 589
49. A. Sigalov, D. Aivazian, and L. Stern Homooligomerization of the cytoplasmic domain of the T cell receptor ζ chain and of other proteins containing the immunoreceptor tyrosine-based activation motif Biochemistry 43 2004 2049 2061
50. A.B. Sigalov Uncoupled binding and folding of immune signaling-related intrinsically disordered proteins Prog Biophys Mol Biol 106 2011 525 536
51. M.A. Amon, M. Ali, V. Bender, Y.N. Chan, I. Toth, and N. Manolios Lipidation and glycosylation of a T cell antigen receptor (TCR) transmembrane hydrophobic peptide dramatically enhances in vitro and in vivo function Biochim Biophys Acta 1763 2006 879 888
52. A.H. Enk, and J. Knop T cell receptor mimic peptides and their potential application in T-cell-mediated disease Int Arch Allergy Immunol 123 2000 275 281
53. A.B. Sigalov Novel mechanistic concept of platelet inhibition Expert Opin Ther Targets 12 2008 677 692
54. F.J. Quintana, D. Gerber, S.C. Kent, I.R. Cohen, and Y. Shai HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation J Clin Invest 115 2005 2149 2158
55. A.B. Sigalov Novel mechanistic insights into viral modulation of immune receptor signaling PLoS Pathog 5 2009 e1000404
56. E. Matalon, O. Faingold, M. Eisenstein, Y. Shai, and D. Goldfarb The topology, in model membranes, of the core peptide derived from the T-cell receptor transmembrane domain Chembiochem 14 2013 1867 1875
57. A. Jonas Reconstitution of high-density lipoproteins Methods Enzymol 128 1986 553 582
58. A.G. Lacko, M. Nair, L. Prokai, and W.J. McConathy Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs Expert Opin Drug Deliv 4 2007 665 675
59. T. Skajaa, D.P. Cormode, E. Falk, W.J. Mulder, E.A. Fisher, and Z.A. Fayad High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis Arterioscler Thromb Vasc Biol 30 2010 169 176
60. C. Bergt, G. Marsche, U. Panzenboeck, J.W. Heinecke, E. Malle, and W. Sattler Human neutrophils employ the myeloperoxidase/hydrogen peroxide/chloride system to oxidatively damage apolipoprotein A-I Eur J Biochem 268 2001 3523 3531
61. S.A. Horst, A. Linner, A. Beineke, S. Lehne, C. Holtje, and A. Hecht et al. Prognostic value and therapeutic potential of TREM-1 in Streptococcus pyogenes-induced sepsis J Innate Immun 5 2013 581 590
62. E.Y. Lin, A.V. Nguyen, R.G. Russell, and J.W. Pollard Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy J Exp Med 193 2001 727 740
63. S. Aharinejad, P. Paulus, M. Sioud, M. Hofmann, K. Zins, and R. Schafer et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice Cancer Res 64 2004 5378 5384
64. J.B. Galloway, K.L. Hyrich, L.K. Mercer, W.G. Dixon, A.P. Ustianowski, and M. Helbert et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 70 2011 1810 1814
65. E. Abraham, R. Wunderink, H. Silverman, T.M. Perl, S. Nasraway, and H. Levy et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group JAMA 273 1995 934 941
66. P.Q. Eichacker, C. Parent, A. Kalil, C. Esposito, X. Cui, and S.M. Banks et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis Am J Respir Crit Care Med 166 2002 1197 1205
67. C.J. Fisher Jr., J.M. Agosti, S.M. Opal, S.F. Lowry, R.A. Balk, and J.C. Sadoff et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group N Engl J Med 334 1996 1697 1702
68. C.J. Fisher Jr., J.F. Dhainaut, S.M. Opal, J.P. Pribble, R.A. Balk, and G.J. Slotman et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group JAMA 271 1994 1836 1843
69. S. Dang, Y. Shen, K. Yin, and J. Zhang TREM-1 promotes pancreatitis-associated intestinal barrier dysfunction Gastroenterol Res Pract 2012 2012 720865
70. S. Gibot, F. Massin, C. Alauzet, C. Montemont, A. Lozniewski, and P.E. Bollaert et al. Effects of the TREM-1 pathway modulation during mesenteric ischemia-reperfusion in rats Crit Care Med 36 2008 504 510